Top 50 Biotechnology VC Funds & Investors in Europe (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
SOSV
VC Fund
|
77 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
Bpifrance
VC Fund
|
73 | France, United States, Switzerland | Seed, Series A | Software, Information Technology, Health Care | $658k–$35M |
|
Sofinnova Partners
VC Fund
|
69 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6M–$102M |
|
UK Innovation & Science Seed Fund
VC Fund
|
56 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Medical | $393k–$14M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
54 | Germany, Switzerland, United States | Seed, Series A | Software, Biotechnology, Information Technology | $909k–$33M |
|
Novo Holdings
VC Fund
|
51 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $8M–$125M |
|
Parkwalk Advisors
VC Fund
|
44 | United Kingdom, United States, Philippines | Seed, Series A, Series B | Biotechnology, Health Care, Software | $982k–$46M |
|
Scottish Enterprise
VC Fund
|
43 | United Kingdom, United States, Japan | Seed, Grant | Biotechnology, Software, Health Care | $104k–$4.1M |
|
Oxford Science Enterprises
VC Fund
|
40 | United Kingdom, United States, Finland | Seed, Series A, Series B | Health Care, Biotechnology, Software | $1.3M–$168M |
|
Kurma Partners
VC Fund
|
35 | France, Switzerland, Spain | Series A, Seed, Series B | Health Care, Biotechnology, Medical | $2.3M–$80M |
|
Seventure Partners
VC Fund
|
35 | France, United States, Germany | Series A, Series B | Biotechnology, Software, Health Care | $3.1M–$65M |
|
Oxford Technology Management
VC Fund
|
34 | United Kingdom, United States | Seed, Series A | Biotechnology, Health Care, Software | $33k–$7.9M |
|
Boehringer Ingelheim Venture Fund
VC Fund
|
31 | United States, Germany, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $1.3M–$50M |
|
Enterprise Ireland
VC Fund
|
29 | Ireland, United States, United Kingdom | Seed, Series A | Software, Health Care, Information Technology | $439k–$12M |
|
Catapult Ventures
VC Fund
|
29 | United Kingdom, United States, Israel | Seed, Series A | Health Care, Biotechnology, Medical | $150k–$26M |
|
Scottish Investment Bank
VC Fund
|
28 | United Kingdom, United States, France | Seed, Series A | Software, Biotechnology, Health Care | $327k–$7M |
|
Mercia Fund Managers
VC Fund
|
27 | United Kingdom, United States, Hungary | Seed, Series A | Software, Health Care, Biotechnology | $196k–$14M |
|
GO CAPITAL
VC Fund
|
26 | France, Canada, Israel | Seed, Series A | Biotechnology, Software, Health Care | $516k–$10M |
|
M Ventures
VC Fund
|
25 | United States, United Kingdom, Switzerland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2.4M–$100M |
|
Epidarex Capital
VC Fund
|
25 | United Kingdom, United States, Germany | Series A, Seed, Series B | Biotechnology, Health Care, Therapeutics | $531k–$55M |
|
Development Bank of Wales
VC Fund
|
24 | United Kingdom, Australia, United States | Seed, Debt Financing | Software, Health Care, Biotechnology | $18k–$3.7M |
|
Centre for the Development of Industrial Technology (CDTI)
VC Fund
|
24 | Spain, United States, France | Grant, Seed | Biotechnology, Health Care, Software | $126k–$5.9M |
|
Elaia
VC Fund
|
24 | France, United States, Spain | Seed, Series A, Series B | Software, Artificial Intelligence, Information Technology | $1.1M–$38M |
|
Karista
VC Fund
|
23 | France, United States, Finland | Seed, Series A, Series B | Software, Biotechnology, Health Care | $713k–$43M |
|
SFC Capital
VC Fund
|
22 | United Kingdom, United States, Canada | Pre-Seed, Seed | Software, Artificial Intelligence, Information Technology | $158k–$2.2M |
|
Archangels
VC Fund
|
22 | United Kingdom, United States | Seed, Series A | Software, Biotechnology, Health Care | $1.3M–$8.3M |
|
Forbion Capital Partners
VC Fund
|
22 | United States, United Kingdom, The Netherlands | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $12M–$176M |
|
HealthCap
VC Fund
|
21 | United States, Sweden, France | Series B, Series A | Biotechnology, Health Care, Medical | $5.7M–$88M |
|
BioInnovation Institute
VC Fund
|
21 | Denmark, Germany, Switzerland | Convertible Note, Pre-Seed, Debt Financing | Biotechnology, Medical, Health Care | $516k–$5.2M |
|
MIG Capital
VC Fund
|
21 | Germany, France, Austria | Series A, Series B | Biotechnology, Health Care, Therapeutics | $1.6M–$54M |
|
IP Group
VC Fund
|
21 | United Kingdom, United States, Australia | Seed, Series A | Health Care, Biotechnology, Therapeutics | $393k–$23M |
|
Omnes Capital
VC Fund
|
21 | France, Germany, United States | Series A, Series B | Software, Biotechnology, Health Care | $3.5M–$43M |
|
Auriga Partners
VC Fund
|
20 | France, United States, Switzerland | Series B, Series A | Biotechnology, Health Care, Medical | $2.2M–$33M |
|
AlbionVC
VC Fund
|
20 | United Kingdom, United States, France | Series A, Seed | Software, Information Technology, Health Care | $2.2M–$20M |
|
O2h Ventures
VC Fund
|
20 | United Kingdom, Hungary | Seed, Series A | Biotechnology, Health Care, Pharmaceutical | $655k–$26M |
|
Future Planet Capital
VC Fund
|
20 | United Kingdom, United States, Canada | Seed, Convertible Note | Biotechnology, Health Care, Software | $897k–$7.9M |
|
Meusinvest (Noshaq)
VC Fund
|
20 | Belgium, France, Germany | Series A, Seed | Biotechnology, Health Care, Medical | $137k–$16M |
|
Idinvest Partners
VC Fund
|
19 | France, United States, Spain | Series B, Series A | Biotechnology, Health Care, Software | $3.3M–$66M |
|
Wren Capital
VC Fund
|
19 | United Kingdom | Seed, Series A | Biotechnology, Health Care, Medical | $1.1M–$32M |
|
Deepbridge Capital
VC Fund
|
19 | United Kingdom, Australia, Singapore | Seed, Series A | Health Care, Biotechnology, Medical | $152k–$15M |
|
GM&C Life Sciences Fund
VC Fund
|
19 | United Kingdom, Italy, Germany | Seed, Series A | Health Care, Biotechnology, Medical | $65k–$4.1M |
|
Northstar Ventures
VC Fund
|
19 | United Kingdom, United States, Indonesia | Seed, Series A | Software, Health Care, E-Commerce | $39k–$9.7M |
|
Newable Private Investing
VC Fund
|
18 | United Kingdom, United States | Seed, Series A | Software, Health Care, Biotechnology | |
|
Cambridge Innovation Capital
VC Fund
|
18 | United Kingdom, United States, Ireland | Series A, Series B, Seed | Biotechnology, Health Care, Therapeutics | $2M–$73M |
|
Hoxton Ventures
VC Fund
|
18 | United Kingdom, United States, Canada | Seed, Series A | Artificial Intelligence, Software, Information Technology | $1.8M–$29M |
|
AdBio partners
VC Fund
|
17 | France, Spain, Belgium | Seed, Series A | Biotechnology, Health Care, Pharmaceutical | |
|
Ysios Capital
VC Fund
|
17 | Spain, United States, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $2.2M–$135M |
|
Oxford Capital
VC Fund
|
17 | United Kingdom, United States, France | Seed, Series A | Software, Health Care, Mobile | $1.5M–$16M |
|
Syncona Partners LLP
VC Fund
|
16 | United Kingdom, United States, Switzerland | Series A, Series B, Seed | Biotechnology, Medical, Health Care | $1.8M–$131M |
|
Octopus Ventures
VC Fund
|
16 | United Kingdom, United States, Germany | Series A, Seed, Series B | Software, Health Care, Information Technology | $1.9M–$46M |
| Access all 50 VC funds in Europe Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Series A
- Geography: France, United States, Switzerland
Investor stats
- Total investments: 989
- Round size: Seed $658k–$6.4M; Series A $2.5M–$35M
- Lead/follow: 22% lead, 78% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Kayrros — Kayrros is the leading advanced data analytics company that helps traders, investors, operators and governments make better decisions.
- Callyope — Callyope is building the first speech-based foundational model to monitor mental health symptoms through low-touch smartphone interactions.
- ErVimmune — Our team is focused on bringing breakthrough immunotherapies in unmet medical needs for cancer patients. Check our work!
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 298
- Round size: Series A $6M–$65M; Series B $10M–$102M; Series C $11M–$100M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- protera — Protera is advancing the science of protein engineering to address some of the most critical problems and opportunities in food, agriculture, the environment and human health. We streamline protein design and development with MADI, our proprietary deep learning algorithm, to predict high value protein products and enzymes with unprecedented speed.Our in-house lab generates small quantities of the new predicted structures to validate their desired performance. Upon lab validation, we collaborate with our clients on next steps to move from pilot to industrial scale production.
- Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
- T-Therapeutics — T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. .
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 130
- Round size: Seed $393k–$5.9M; Series A $2.9M–$14M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2014
Portfolio highlights
- NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
- Presymptom Health — Enabling Early Diagnosis for better infection & sepsis care. With faster, more accurate testing. Presymptom Health is a medtech company developing a portfolio of patented diagnostic tests that are both faster and more reliable than those available today. Accelerate diagnosis. Address antimicrobial resistance.
- Pencil Biosciences — Pencil Biosciences is pioneering the next generation of gene editing. We are developing a fully synthetic, RNA-guided platform designed to overcome the limitations of current technologies.
High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 542
- Round size: Seed $909k–$6.5M; Series A $3M–$33M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $522M in 2022
Portfolio highlights
- Sdui — Sdui is the solution for mobile communication in schools. With amazingly easy features for messaging, timetables and a wide range of third party integrations, the app digitizes processes and reduces administrative effort. Within two years, Sdui has reached hundreds of institutions and grown a serious reputation in the educational market.
- envelio — We are driving forward the energy transition with our smart grid solutions for grid operators. Get information now and plan smart!
- Atriva Therapeutics — Therapies against viral infections. First-in-class host-targeting therapies to treat respiratory viral infections, including COVID-19 and influenza.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 314
- Round size: Series A $8M–$100M; Series B $12M–$125M; Series C $30M–$115M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
- Tobira Therapeutics — Tobira Therapeutics, Inc., a biotechnology company, engages in the research, discovery, acquisition, development, and commercialization of antiviral compounds for the treatment of life-threatening and life-altering infectious diseases. It develops TBR-652 and TBR-220 antagonists for the treatment of HIV/AIDS, hepatitis, and other associatedinfectious conditions. The company was founded in 2006 and is based in Princeton, New Jersey.
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Philippines
Investor stats
- Total investments: 255
- Round size: Seed $982k–$4.7M; Series A $1.6M–$13M; Series B $2M–$46M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Nozzle.ai — Award-winning Amazon analytics tools designed to provide FBA Amazon Sellers with unique customer insights. Try for Free.
- Phasecraft — Using disruptive theory to unlock the power of quantum computing
- Echion Technologies — Echion Technologies is a spinout from the University of Cambridge Engineering Department, using proprietary battery active materials to develop next-generation Li-ion batteries.
Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Seed, Grant
- Geography: United Kingdom, United States, Japan
Investor stats
- Total investments: 286
- Round size: Seed $318k–$3.4M; Grant $104k–$4.1M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Moblyze — Moblyze is the first talent marketplace app for the energy transition.
- uFraction8 — Multi-award-winning, innovative, microfluidics-based filter systems to provide bio-manufacturers with energy-efficient & ultra-scalable bioprocessing systems.
- Smart Green Shipping — smart green shipping alliance. economically, socially and environmentally superior shipping solutions.
Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Finland
Investor stats
- Total investments: 161
- Round size: Seed $1.3M–$10M; Series A $5M–$46M; Series B $8.5M–$168M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $327M in 2022
Portfolio highlights
- Mode Labs — Mode Labs provide robust, continuous, and remote real-time chemical sensors.
- Amber Therapeutics — Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology
- Pepgen — PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides,and they are advancing novel conjugate therapeutics to the clinic.
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Seed, Series B
- Geography: France, Switzerland, Spain
Investor stats
- Total investments: 128
- Round size: Seed $2.3M–$13M; Series A $3.8M–$74M; Series B $8.8M–$80M
- Lead/follow: 50% lead, 50% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- Medlumics — Medlumics is a medical device start-up born in 2009 from a compromise with improving human living standards by means of technology.
- Vico Therapeutics — Pioneering RNA-based science to target the root cause of rare genetic neurological diseases VO659: The first clinical candidate directly targeting the CAG repea
- Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Series A, Series B
- Geography: France, United States, Germany
Investor stats
- Total investments: 213
- Round size: Series A $3.1M–$24M; Series B $3.3M–$65M
- Lead/follow: 36% lead, 64% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Otoqi — Otoqi is a vehicle delivery platform that develops connected services and logistics solutions for the automotive professionals.
- Karmen — Karmen offers revenue-based financial solutions such as venture capital and loans to accelerate business growth for SaaS companies.
- Flexvelop — Flexvelop combines financial technology with circular economy to add innovative values to the core function of equipment funding.Local vendors and online-shops integrate Flexvelop as a seamless embedded payment option. Business customers are now able to #flex new equipment per click right at the point of sale. Insurance is already covered, andour customers have now the weekly option, to buy- or return their equipment, easily. This enables a new world of worry-free and flexible business growth.We #flex business equipment from €300 up to €20.000 per item; e.g. coffee-machines, laptops, gym- or dental-equipment,... anything you need for your business.NEXT GENERATION PAYMENTS + Technological Innovation: fully automatic embedded payment option + Economical Innovation: optionality (rent/buy/return) + insurance included + Ecological Innovation: sustainability (contributing to a circular economy) = Enabling worry-free flexible business developmentForget renting. Forget leasing. Grow smart - flex it!
Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 107
- Round size: Seed $33k–$2.1M; Series A $786k–$7.9M
- Lead/follow: 7% lead, 93% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- OrganOx — OrganOx Limited was founded in 2008 to exploit normothermic preservation technology invented by Prof Peter Friend and colleagues and further developed by Prof Constantin Coussios at the University of Oxford.
- CryoLogyx — CryoLogyx Ltd. trading as CryoLogyx registered in England and Wales 13078280. VAT registered 373846855. Our registered office address is CryoLogyx Ltd, The Venture Centre, Sir William Lyons Road, Coventry, CV4 7EZ.
- Metacarpal — Metacarpal design upper-limb prosthetics without compromise. We aim to make the most robust, functional hand prosthesis that people love wearing because it works so effectively and looks so beautiful. Be proud to show your artificial side!
Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 94
- Round size: Seed $1.3M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — raised $250M in 2018
Portfolio highlights
- Perfood — Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases. Using sensors, lab results, and holistic analyses, they derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. They call this approach digitaltherapeutics. A digital solution that is just as effective as a drug. But without side effects.
- Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
- Rinri Therapeutics — Rinri Therapeutics has been founded on pioneering research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield.
Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Series A
- Geography: Ireland, United States, United Kingdom
Investor stats
- Total investments: 485
- Round size: Seed $439k–$3.3M; Series A $2.2M–$12M
- Lead/follow: 19% lead, 81% follow
- Last fund: May invest from a new fund soon — raised $1.1M in 2021
Portfolio highlights
- Tirlan — Tirlan is an agricultural company that supplies agri-food and farm input materials to the framing sector.
- Lakeland Dairies — Lakeland Dairies, a major dairy processing co-operative, operates within a fifteen county catchment area across the northern half of the island of Ireland. The Group processes about one billion litres of quality milk annually into a range of value added dairy foodservice products and functional dairy food ingredients.
- Ulysses Neuroscience — We are your vanguard CRO and translational partner, dedicated to advancing clinical and preclinical research for neuropsychiatric, neurodegenerative, and rare neurological disorders.
The team behind Catapult Ventures are among the most experienced venture capital investors in the UK.Their experience spans a range of sectors from healthcare and pharmaceuticals to luxury consumer brands, manufacturing and software, as well as all stages: from start-ups and pre-revenue IP developers to company floatation and billions of poundsin revenue. Their administration team is equally experienced with each member having more than 10 years experience in a venture capital environment.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Israel
Investor stats
- Total investments: 104
- Round size: Seed $150k–$5.6M; Series A $1.6M–$26M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Rinicare — Rinicare is Lancaster-based SME that offers innovative technology solutions for healthcare applications.
- Pickle Robot — We make robots that unload trucks without retrofitting the warehouse
- Anello Photonics — Anello Photonics is founded by pioneers in silicon photonics and inertial navigation. The patented Anello SiPhOG gyroscope offers an affordable mass-market sensor with true Optical Gyroscope performance. The company is headquartered in Silicon Valley and funded by leading venture capital firms.
Speak with our Entrepreneurship and Investment teams, who can help you find sources of finance, engage with funders and secure investment to grow your business.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 208
- Round size: Seed $327k–$3.1M; Series A $1.6M–$7M
- Lead/follow: 11% lead, 89% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
- IOTech — Discover IOTech Systems. Deploy, manage, and scale AI-driven, data-rich industrial systems at the edge with our open edge data platform.
- Administrate — Administrate is a comprehensive, configurable training management platform that helps organizations streamline enterprise learning and development. Organize, deliver, plan, automate, analyze, and scale your training program effectively -- all through one system. Deliver multi-modality learner experiences, maximize training resources, anddemonstrate business results with insight-rich reporting. Hundreds of organizations serving millions of learners choose Administrate to manage their training program.
Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Hungary
Investor stats
- Total investments: 133
- Round size: Seed $196k–$2M; Series A $2M–$14M
- Lead/follow: 67% lead, 33% follow
- Last fund: May invest from a new fund soon — last raise in 2013
Portfolio highlights
- 4D Medicine —
- Adludio — Adludio is the AI-powered platform that delivers interactive mobile advertising. By using data to design your ad creative, and algorithms to optimize your campaigns, Adludio makes sure you win the battle for brand attention.
- Role Mapper Technologies — Automate and transform how you design and manage job descriptions across your organisation. Hire, retain and grow an inclusive and diverse workforce with AI powered Intelligent Job Design.
GO Capital is an independent management company and a major player in regional Seed and Venture Capital since 2003. With offices in Brittany, Pays de la Loire, Normandy, Centre-Val de Loire and the South of France, GO Capital contributes to the financing of responsible innovation in these regions. With a team of investors with complementarysectoral experience, we have a solid track-record in DeepTech. GO Capital has nearly 400 million euros under management, and mainly finances technology leaders in the digital and healthcare sectors and in the industry of the future.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Seed, Series A
- Geography: France, Canada, Israel
Investor stats
- Total investments: 130
- Round size: Seed $516k–$6.6M; Series A $2.1M–$10M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Episto — Episto helps you collect ultra-authentic insights from your targets, anywhere in the world, simply and instantly
- AISPRID — AISPRID is a robotic company that manufactures autonomous robots for soft fruit picking.
- Axomove — Axomove is an e-health app that specializes in video physical exercises.
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 163
- Round size: Seed $2.4M–$21M; Series A $5.2M–$45M; Series B $15M–$100M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- CellFE — We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
- UNISERS — Developing solutions for Universal Contamination Analysis. Working with cutting edge technologies to revolutionize contamination control.
- Polaris Electro-Optics — Polaris Electro-Optics empowers integrated photonics for communications and computation.
Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 47
- Round size: Seed $531k–$8.5M; Series A $2.6M–$40M; Series B $2.4M–$55M
- Lead/follow: 49% lead, 51% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Leucid Bio — CAR T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers.
- Ryme Medical — Ryme Medical is a device company developing a novel catheter-based treatment for COPD
- Harness Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Debt Financing
- Geography: United Kingdom, Australia, United States
Investor stats
- Total investments: 211
- Round size: Seed $327k–$3.7M; Debt Financing $18k–$2M
- Lead/follow: 58% lead, 42% follow
- Last fund: May invest from a new fund soon — raised $25M in 2018
Portfolio highlights
- Forth — Forth are a group of clinical and digital experts who are passionate about healthcare. They’re part of a new breed of digital healthcare companies who are transforming people’s relationship with their health by using technology to give them more information and help them gain greater control.
- enModus — Experience the thrill of competing against other players in online casino tournaments! These events offer a unique opportunity to showcase your skills and
- Antiverse — Designing biologics for 100 challenging targets
The Center for Industrial Technological Development (CDTI) is a public corporation under the Ministry of Economy and Competitiveness, which promotes innovation and technological development of Spanish companies. Is the entity which channels requests for funding and support to projects I + D + i of Spanish companies in the national andinternational levels. The CDTI has a staff of more than 300 people formed three quarters of engineers and graduates. Although the bulk of the infrastructure of the CDTI is located in Madrid, the Centre offers Spanish companies a strategic network of offices and representatives abroad (Japan -SBTO (Spain Business and Technology Office) - Belgium -SOST (Spain Office of Science and Technology) and Permanent Secretariat Eureka-, Brazil -FINEP (Financier of Studies and Projects) -, Korea, Chile, Morocco, China, India, Mexico and USA) to support them in their technological activities of type int .
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Grant, Seed
- Geography: Spain, United States, France
Investor stats
- Total investments: 175
- Round size: Seed $562k–$5.9M; Grant $126k–$861k
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- Xoople — Xoople operates as an earth intelligence company. Xoople powers the next generation of Earth data intelligence to achieve a systematic understanding of physical changes on the Earth’s surface.
- TetraxAI — TetraxAI helps renewable energy developers and investors automate due diligence and risk assessment - 100x faster, 10x cheaper, with full legal traceability.
- Golden Owl —
Elaia is French venture capital firm focused on European digital and deep tech startups, from early stage to growth developpement. We back tech disruptors.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Series B
- Geography: France, United States, Spain
Investor stats
- Total investments: 210
- Round size: Seed $1.1M–$9.9M; Series A $2.2M–$27M; Series B $4.2M–$38M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Elevo — Elevo is a Paris-based performance management platform.
- Vibe — Advertise your brand on CTV & OTT content with Vibe's self-serve ad platform to target hundreds of channels & networks and reach millions of households.
- Traefik Labs — Cloud-native, GitOps-driven API runtime solutions for demanding DevOps and Platform Engineers with diverse use-cases, environments, and deployment models.
Karista is an early-stage venture capital firm created in 2001 investing in Health, Digital, Tech, and NewSpace.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Series B
- Geography: France, United States, Finland
Investor stats
- Total investments: 144
- Round size: Seed $713k–$6.6M; Series A $1.2M–$15M; Series B $2.5M–$43M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- CYSEC — Secure your sensitive data in the cloud and in the edge with ARCA Trusted OS and open the door to innovation with confidential computing.
- Stootie — Stootie is a buyer-focused classifieds platform. It's mobile. It's local. And it's quick. Really quick!This is the tool you use to get that phone power outlet you forgot when you're working in a Starbucks. Or pretty much anything else. Anywhere. Anytime.The keywords of Stootie are : marketplace, P2P business, local,mobile, realtime, platform.Stootie is currently available on iOS and Android.
- Exotrail — Exotrail is an end-to-end space mobility operator. Our mission is to enable small satellites to move in space, optimise their deployment, increase their service performance, and reduce space pollution.
Discover the UK's leading SEIS Fund, offering tax-efficient investments in innovative startups. Join thousands of savvy investors and raise capital for your business with SFC Capital.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Pre-Seed, Seed
- Geography: United Kingdom, United States, Canada
Investor stats
- Total investments: 330
- Round size: Seed $159k–$2.2M; Pre-Seed $158k–$840k
- Lead/follow: 42% lead, 58% follow
- Last fund: May invest from a new fund soon — raised $1.9M in 2019
Portfolio highlights
- Elaitra — Elaitra’s breast cancer platform includes a Generative LLM for voice-based patient engagement, and a unique AI reading tool that helps doctors read 3D X-Rays. Operating in USA & UK. FDA 510(k) and UK regulator approved.
- Sages — Biodegradeable, non-polluting, low-impact and vibrant dyes extracted from food waste.
- WeFindFlats — Live and work anywhere, without housing worries.
Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 84
- Round size: Seed $1.3M–$3.9M; Series A $1.6M–$8.3M
- Lead/follow: 54% lead, 46% follow
Portfolio highlights
- 1inhaler — 1inhaler operates as a developer of drug delivery device.
- BioCaptiva — BioCaptiva develops liquid biopsy technology devices to diagnose and monitoring to detect cancers.
- Administrate — Administrate is a comprehensive, configurable training management platform that helps organizations streamline enterprise learning and development. Organize, deliver, plan, automate, analyze, and scale your training program effectively -- all through one system. Deliver multi-modality learner experiences, maximize training resources, anddemonstrate business results with insight-rich reporting. Hundreds of organizations serving millions of learners choose Administrate to manage their training program.
Impacting the future of medicine.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, The Netherlands
Investor stats
- Total investments: 171
- Round size: Series A $14M–$176M; Series B $12M–$155M; Series C $12M–$113M
- Lead/follow: 50% lead, 50% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- F2G — F2G is a biopharmaceutical company developing novel therapies for life-threatening fungal infections.
- Noema Pharma — DRIVING BETTER OUTCOMES Advancing therapeutics designed to deliver superior clinical benefit across both orphan and broader neurology indications Who we are ...
- Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: United States, Sweden, France
Investor stats
- Total investments: 121
- Round size: Series A $5.7M–$55M; Series B $14M–$88M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $209M in 2019
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- HelloBetter — HelloBetter (hellobetter.de) was founded in 2015 under the name GET.ON Institut für Online Gesundheitstrainings GmbH (geton-institut.de) by internationally renowned research psychologists, and in close partnership with one of the largest public health care insurance companies in Germany (BARMER). HelloBetter is a pioneer in the field of e-mentalhealth and a leading provider of online mental health courses. Its work has a strong scientific basis – the courses were developed, evaluated, and implemented in a practice setting, and their effectiveness has been proven in 33 randomized controlled trials according to the highest standards of scientific practice. HelloBetter offers the widest range of evidence-based online mental health courses worldwide, with 11 digital courses covering 8 problem areas (stress, depression, insomnia, depression in the case of chronic illness, chronic pain, alcohol consumption, excessive worry, and panic and anxiety).In October 2021, the digital therapeutic 'HelloBetter Stress and Burnout' has been permanently approved by the German Federal Institute for Drugs and Medical Devices (BfArM) as a Digital Health Application (DiGA) and thus is available by prescription free of charge for more than 50 million adults. It is the world’s first and so far only prescription digital therapeutic for the treatment of burnout symptoms.Through diverse cooperations with national and international research groups (including FAU Erlangen, University of Ulm, VU Amsterdam, and Harvard University) HelloBetter finds practical applications for the latest research innovations. Our products and our team have been awarded numerous national and international prizes. These include the Novartis & Sandoz/Hexal Digital Health Prize 2018, the Comenius Award of the European Federation of Psychologists’ Association, and the Good Practice in Mental Health & Wellbeing seal of approval as part of the EU Compass 2018, which recognises high-quality mental health initiatives in Europe in order to guide health care providers to effective and proven services.
- Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.
BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Convertible Note, Pre-Seed, Debt Financing
- Geography: Denmark, Germany, Switzerland
Investor stats
- Total investments: 72
- Round size: Pre-Seed $516k–$5.2M; Debt Financing $549k–$1.4M; Convertible Note $549k–$1.5M
- Lead/follow: 90% lead, 10% follow
Portfolio highlights
- Zeta Diagnostics — First-in-class hardware-and-software-as-a-service diagnostics for the 400M suffering from middle ear problems
- Loma Therapeutics — Loma Therapeutics is developing targeted immunotherapy for the effective and safe treatment of HPV infection, dysplasia, and cancer patients.
- metaLead Therapeutics — metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment.
MIG Capital is one of the leading German VC Investors. We invest in European Deep Tech and Life Sciences from early to late stage (Seed, Series A, and beyond). We use investments to shape a better tomorrow, today. Our team currently manages 17 MIG public venture capital funds regulated by BaFin, the German financial markets authority. These fundsoperate with more than EUR 1.2 billion capital committed by >60,000 private investors across Germany and Austria.Today, our portfolio consists of 30 companies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B
- Geography: Germany, France, Austria
Investor stats
- Total investments: 93
- Round size: Series A $2.2M–$28M; Series B $1.6M–$54M
- Lead/follow: 45% lead, 55% follow
- Last fund: May invest from a new fund soon — raised $70M in 2014
Portfolio highlights
- AMSilk — AMSilk produces and distributes high-quality silk biopolymers for use in textile products, medical devices, and cosmetics.
- Look Up Space — Lookup space is the next global leader for space safety, security and sustainability
- ASTRA Therapeutics — Astra - Therapeutics
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Therapeutics
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Australia
Investor stats
- Total investments: 188
- Round size: Seed $393k–$7.6M; Series A $2M–$23M
- Lead/follow: 21% lead, 79% follow
- Last fund: May invest from a new fund soon — raised $125M in 2014
Portfolio highlights
- Lumai — Lumai delivers optical compute for the inference era, enabling up to 50x AI performance and 90% less power. Supports billion-parameter LLMs today.
- AudioScenic — THE NEW DIMENSION IN SOUND
- Intrinsic Semiconductor Technologies — Exciting new developments around the Internet of Things, Big Data, autonomous vehicles, and Artificial Intelligence highlight how our approach to computation must fundamentally change.
Omnes VC is the Venture Capital arm of Omnes Capital, a leading private equity firm dedicated to energy transition and innovation with €4.8 billion in assets under management and a 20 year + experience in: venture capital, buyout & growth capital, private debt, renewable energy, co-investment, secondary funds of funds. Omnes Capital is fullyindependent.With 65 business sales including 14 IPOs carried out in 16 years, Omnes VC is one of the key players in France in financing innovative SMEs with expertise in both Technology and Healthcare sectors. Omnes VC has supported 120 companies and has invested more than €500M in businesses such as Scality, Novaled, BioVex, arGEN-X, Pixium, Blablacar.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Series A, Series B
- Geography: France, Germany, United States
Investor stats
- Total investments: 175
- Round size: Series A $3.5M–$38M; Series B $4.4M–$43M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $403M in 2020
Portfolio highlights
- Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
- Sekoia.io — Sekoia.io provides cyber teams with a SOC platform that can respond to security incidents, regardless of the attack surface.
- Amakem — Easy, affordable options for you to obtain the domain you want. Safe and secure shopping.
Since 1998, AURIGA PARTNERS, an independent Venture Capital firm, has been managing several early stage funds specializing in Information Technology and Life Sciences.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: France, United States, Switzerland
Investor stats
- Total investments: 128
- Round size: Series A $2.2M–$14M; Series B $3.8M–$33M
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- Amplitude — Amplitude is a leading manufacturer of femtosecond lasers. We are laying the foundations for advances in science, industry, and health care.
- Pherecydes Pharma — Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to itsouter membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria.
- Median Technologies — We harness the power of Imaging Phenomics to contribute to the development of next generation treatments and care strategies for patients in need.
AlbionVC supports visionary founders and technologies with long-term capital and scale-up know-how. Founded in 1996, it was amongst the first to back leading global success stories such as Booking.com, Egress, Quantexa and Oviva. With £1bn in AUM and over 100 exits successfully realised, it funds venture breakthroughs that drive real outcomes forfounders, investors and society. AlbionVC is the technology investment arm of Albion Capital Group, which is authorised and regulated by the Financial Conduct Authority. For more information please visit: https://albion.vc/
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Series A, Seed
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 159
- Round size: Seed $2.2M–$13M; Series A $3.8M–$20M
- Lead/follow: 42% lead, 58% follow
Portfolio highlights
- Oviva — Oviva is digitizing the treatment of type 2 diabetes and obesity through a unique behavior change platform.They have developed unique, personalised behaviour change programmes that combine smartphone app and learning portals to support dietitian-led behaviour change for conditions such as type 2 diabetes and complex obesity. Their approach allowspatients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions.Oviva was founded in 2013 and is based in London, England.
- uMotif — uMotif provides the most modern eCOA/ePRO and eConsent platform designed to power clinical and real-world research.
- Ophelos — Flexible repayments, with an empathetic approach. Discover how we can help you get debt-free on your terms and timescales.
Transforming UK biotech breakthroughs into impact. o2h Ventures offers SEIS/EIS and growth-stage funds to back visionary teams from seed to clinical success.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Series A
- Geography: United Kingdom, Hungary
Investor stats
- Total investments: 39
- Round size: Seed $655k–$7.9M; Series A $1.9M–$26M
- Lead/follow: 46% lead, 54% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Atelerix — Discover Atelerix's hypothermic hydrogels for reliable cell preservation and ambient temperature shipping. Ensure fresh, viable cell samples.
- Neurocentrx — Neurocentrx is a specialty pharma company, developing and in-licensing products in pain, palliative care, psychiatry and mood disorders.
- Alevin Therapeutics — Our mission is to develop safe and effective medicines for patients with life-threatening diseases through targeted integrin therapies
Brilliant Ideas. Brilliant People. Brilliant Minds.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note
- Geography: United Kingdom, United States, Canada
Investor stats
- Total investments: 142
- Round size: Seed $897k–$7.9M
- Lead/follow: 7% lead, 93% follow
- Last fund: Likely still investing — raised $23M in 2022
Portfolio highlights
- Zentraxa — NATURE ENGINEERED FOR PURPOSE Through millions of years of evolution, nature has found solutions to the most difficult problems. Inspired by the diversity of nature, we precision engineer bespoke biomaterials to meet the toughest challenges across
- iFast Diagnostics — iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.
- Vitarka Therapeutics — Vitarka Therapeutics has engineered an intracellular drug delivery technology, EndoPore, using pore forming proteins for intracellular targets.
Noshaq offers financial services to help businesses develop.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed
- Geography: Belgium, France, Germany
Investor stats
- Total investments: 76
- Round size: Seed $137k–$6M; Series A $3.3M–$16M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- TrustUp — TrustUp is the home contractors platform, connects homeowners with verified quality home improvement.
- Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series B, Series A
- Geography: France, United States, Spain
Investor stats
- Total investments: 252
- Round size: Series A $3.3M–$24M; Series B $7.8M–$66M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $88M in 2021
Portfolio highlights
- Ornikar — Ornikar is an online driving school that offers radically cheaper, uncomplicated and faster offer to obtain a driving license.Ornikar relies on a network of state-qualified teachers to offer an apprenticeship in mobile driving at reduced prices. The cmpany is an an online driving school more in tune with the demand of current and futuregenerations.The company's mission is to make the driver's license exam cheaper and its learning more enjoyable.
- Glovo — Glovo delivers the best products of your city in less than 1 hour
- Stanley Robotics — Stanley Robotics is a DeepTech business helping the transportation and logistics industries digitalise and robotise outdoor operations.
Wren is an angel investor in science, engineering and software. They founded Wren in 2011 and have invested in 50 companies so far.Wren is well known in the early stage investment community and has co-invested with a wide range of both angel and institutional investors. From software and semiconductors to genome editing, and from medical devicesto satellites, they are interested in sectors where technical ingenuity and hard work can produce long term value. They look for people with a deep understanding of their markets. The founders they invest in are smart and they get things done.Wren typically invests £50,000 to £200,000 per funding round. Difficult problems take time to solve, so they are patient with their investments. Their aim is to get deals done and they take a pragmatic approach to doing so.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 32
- Round size: Seed $1.1M–$5.2M; Series A $2M–$32M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Spotta — Spotta's smart pest systems help pest control monitor and identify pests. Solutions for hospitality, care homes, agriculture, farming and forestry.
- MitoRx Therapeutics — Developing revolutionary mitochondrial-protective therapeutics which reverse mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration. MitoRx Therapeutics' first-in-class first-in-target platform has potential to arrest the progression of some of the most challenging diseases.
- Monument Therapeutics — Monument Therapeutics is a biotechnology company intended to develop drugs to treat serious diseases of the central nervous system.
Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Australia, Singapore
Investor stats
- Total investments: 82
- Round size: Seed $152k–$2.6M; Series A $2M–$15M
- Lead/follow: 74% lead, 26% follow
- Last fund: Likely still investing — raised $1.4M in 2022
Portfolio highlights
- upLYFT — upLYFT is working on the next generation of smart wearables to help with musculoskeletal issues related to aging. Also working with pro athletes to help sporting individuals train harder and break records.
- GeneralPractice.AI — General Practice. AI is an advanced, AI-powered platform designed to transform primary care and general practice by streamlining clinical workflows, enhancing patient engagement, and reducing administrative burdens for healthcare professionals. It aims to revolutionize primary care by harnessing artificial intelligence to improve both clinical andadministrative aspects of general practice, ultimately delivering more efficient, personalized, and effective healthcare.
- Spotlight Pathology — Spotlight Pathology develops decision support tools powered by artificial intelligence (AI) to help in the diagnosis of blood cancers.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: United Kingdom, Italy, Germany
Investor stats
- Total investments: 33
- Round size: Seed $65k–$936k; Series A $1.8M–$4.1M
- Lead/follow: 67% lead, 33% follow
Portfolio highlights
- Maxwellia — A contraceptive pill, Lovima, is now available to buy without a prescription.
- Acea Health — Acea Health is a digital healthcare company developing an application called Flynotes - a new digital consent platform. Flynotes analyses a number of factors, including the patient’s background, to deliver personalised risks and benefits. Flynotes aims to be the go-to solution for consent in healthcare. .
- Nexus Labs (Surgical Teaching) — Nexus Labs is an interactive learning resource for medical students.
Northstar Ventures invests venture capital in early and later stage, high growth companies tackling global challenges, focusing on climate tech and healthy ageing.
Show more...Investment focus
- Industry: Software, Health Care, E-Commerce
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Indonesia
Investor stats
- Total investments: 189
- Round size: Seed $39k–$1.8M; Series A $851k–$9.7M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- H2CHP — H2CHP's Free Piston Engine Technology enables your transition to green energy with the reliability & confidence of fuel flexibility.
- NunaBio — NunaBio operates as a privately-owned specialist DNA development company. NunaBio engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities.
- Moralbox —
Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States
Investor stats
- Total investments: 102
- Lead/follow: no public data
Portfolio highlights
- Delta g — Delta g Limited is a quantum technology and gravity gradiometry company. A spin-out from the University of Birmingham our technology has applications in industries as varied as civil engineering, infrastructure, defence, rail, navigation and resource exploration. Experts from science, engineering an
- Weldfast — Weldfast is a manufacturer and supplier of welding consumables, abrasives, chemicals, premium gas equipment, and safety products.
- EarSwitch — Empowering new ways to control and connect with the world through in-ear biometric switch and sensor technology
As a team, we have a passion for science and its potential to drive change. Through our expertise and our position in one of the country's most powerful science and technology ecosystems, we're able to identify and support the most promising entrepreneurs in knowledge intensive businesses and help them achieve their vision.With our financial backing and expert guidance, we're excited to enable the pioneers in life sciences and deep tech to create world-leading companies whose unique ideas bring financial success and global impact.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Seed
- Geography: United Kingdom, United States, Ireland
Investor stats
- Total investments: 97
- Round size: Seed $3.9M–$23M; Series A $2M–$73M; Series B $8.5M–$65M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Immutrin — Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively andspecifically remove established amyloid fibrils.
- Trent AI — Trent AI creates AI applications and agent security management software. It aids in risk assessment and mitigation in systems utilizing autonomous or semi-autonomous software agents. The company's technology monitors agent activity across APIs, tools, and workflows. It continuously assesses security posture via iterative scanning andcontextual understanding of system architectures.
- Forefront RF — Forefront RF tunable duplexer technology expands the accessibility of all mobile devices by unlocking SDR capabilities in the RFFE front end.
Hoxton Ventures focuses on startups that either disrupt existing industries or invent entirely new market categories. Hoxton typically invests between $500,000 and $5 million into pre-seed, seed, and Series A stage companies, and follows its capital through the life of the company. The firm is based in London and invests all across Europe.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Information Technology
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Canada
Investor stats
- Total investments: 128
- Round size: Seed $1.8M–$10M; Series A $5M–$29M
- Lead/follow: 43% lead, 57% follow
Portfolio highlights
- CuspAI — CuspAI is a revolutionary AI startup that is developing a platform for next-generation materials to address global sustainability and renewable energy concerns. CuspAI uses cutting-edge generative AI, deep learning, and molecular simulation to accelerate the material design process. Their platform works similarly to a search engine for materials,allowing users to request certain properties for new materials on demand.
- Malted AI — We create specialised intelligence that turns data into action, to power financial services of the future.
- Fabrica AI — Fabrica AI offers a revolutionary platform for faster robot development, using custom hardware designs and learned optimal control to increase efficiency while minimizing complexity and cost. With a vision for a future where robot development takes days, not years.
AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Series A
- Geography: France, Spain, Belgium
Investor stats
- Total investments: 24
- Lead/follow: no public data
Portfolio highlights
- Cephagenix — Cephagenix focuses on identifying and developing new, effective migraine therapies.
- Tenpoint Therapeutics — Tenpoint Therapeutics Ltd. is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye.
- Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.
Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Spain, United States, Switzerland
Investor stats
- Total investments: 78
- Round size: Series A $2.2M–$63M; Series B $17M–$135M; Series C $27M–$80M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
- Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
- Prexton Therapeutics — Voici la page d'accueil du site web
Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.
Show more...Investment focus
- Industry: Software, Health Care, Mobile
- Stage:Seed, Series A
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 147
- Round size: Seed $1.5M–$3.9M; Series A $3.2M–$16M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $56M in 2015
Portfolio highlights
- eporta — eporta is Europe's leading B2B commerce platform for the furnishings industry, active in over 80 countries around the world.
- UltraSoC Technologies — UltraSoC Technologies is an independent provider of SoC infrastructure to enable rapid development of embedded systems based on advanced SoC devices. Its head office is in Cambridge and it has research and development labs in Colchester.
- Intent HQ — Intent builds AI that understands human intent. On-device processing. Zero personal data exported. 300M+ profiles. 49 patents.
Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Series A, Series B, Seed
- Geography: United Kingdom, United States, Switzerland
Investor stats
- Total investments: 50
- Round size: Seed $1.8M–$17M; Series A $17M–$110M; Series B $24M–$131M
- Lead/follow: 58% lead, 42% follow
Portfolio highlights
- iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
- Apini Therapeutics — Apini is a creating novel small chemical two most prevalent types of inflammatory bowel disease.
- Purespring Therapeutics — A precision nephrology company leading the development of targeted, first-in-class genetic therapies to preserve kidney function.
We provide venture capital investment for the people, ideas and industries that will change the world. Learn about what we do and the kind of founders we back.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Seed, Series B
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 357
- Round size: Seed $1.9M–$11M; Series A $3M–$21M; Series B $7.5M–$46M
- Lead/follow: 57% lead, 43% follow
- Last fund: May invest from a new fund soon — raised $101M in 2019
Portfolio highlights
- CertiVox — CertiVox solutions deliver simple, powerful information security to all things Internet (mainframes, too!), protecting business and individual privacy through the cloud and at rest. CertiVox was founded in 2009 to provide technology and services based on a simple belief: that everyone deserves the right to secure their information exchangessimply and easily. CertiVox's leading-edge encryption, key management and identity management solutions are currently in use at hundreds of the world’s leading corporations and used by individuals across the globe to protect their privacy.The companies passion is to create and share unique, cutting-edge cryptographic innovations for enterprise cloud computing and all things Internet. CertiVox are the only company in the global market today that has the technology in place to arm businesses and individuals with easy-to-use certificateless security solutions for any device and platform.Whether you are a business that wants to safeguard your company’s intellectual property, an ISV or SaaS provider that needs to embed cryptography and key management into your application, or an individual who wants to preserve the privacy of your personal data, CertiVox gives you the power to secure your information for all things Internet.CertiVox’s leading-edge solutions – including MIRACL (Multiprecision Integer and Rational Arithmetic C/C++ Library) Cryptographic SDK, on-demand encryption Key Management Service (KMS) and Identity Management Service (IDMS) – enable cloud service providers, independent software vendors (ISVs), communication providers, and smart device and semiconductor manufacturers to secure their voice and data communication solutions with ease.The PrivateSky Secure Information Exchange Service (SIX) gives individuals, businesses and their partners and customers easy-to-use tools to quickly encrypt email, files and documents without complex infrastructure or user burden. Compliance with mandatory encryption and privacy statues has never been easier.The bottom line: CertiVox's revolutionary certificateless cryptography, identity and key management solutions have taken the hassle out of Internet security, making it easy to securely exchange your information in any form, any time.
- Mojo — Join 600,000+ men worldwide using AI-powered coaches to build a performance mindset and take back control of their love lives.
- Phlux Technology — We develop, manufacture and supply innovative communication and vision components
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology VC Funds in Europe investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 VC funds investing in Europe Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!